(1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one

1.  作為有生命危險病情的輔助療法，推薦劑量是30 ㎎/㎏以至少30分鐘時經靜脈投藥。
2.  依據臨床需求而定，此種劑量可於醫院內每4-6小時重複投藥一次共計48小時。 

Elimination
Plasma t ½ is longer than 3.5 h.

Onset
Onset is 6 to 48 h (IM).

Peak
Times to peak effect are 4 to 8 days (IM) and 1 to 2 h (oral).

Duration
Durations are 1.25 to 1.5 days (oral) and 1 to 4 wk (IM).

Anticholinesterases
May antagonize anticholinesterase effects in myasthenia gravis.

Barbiturates
May decrease pharmacologic effect of methylprednisolone.

Hydantoins, rifampin
May increase Cl and decrease efficacy of methylprednisolone.

Ketoconazole
May decrease Cl of methylprednisolone.

Macrolide antibiotics
Significantly decreases methylprednisolone Cl; may need to decrease dose.

Salicylates
May reduce serum levels and efficacy of salicylates.